NCT05596851 is a clinical trial in Prostate Cancer, sponsored by European Institute of Oncology.

Who is sponsoring NCT05596851?

NCT05596851 is sponsored by European Institute of Oncology.

What condition does NCT05596851 study?

NCT05596851 studies Prostate Cancer, Positron Emission Tomography, PSMA.

Is NCT05596851 still recruiting?

NCT05596851 is currently status unknown. Last updated 27 October 2022.

Last reviewed 2022-10-27 · How we verify

NCT05596851

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Radio-guided Surgery With DROP-IN Beta Probe for 68Ga-PSMA, in High-risk Prostate Cancer Patients Eligible for Robotic-assisted Radical Prostatectomy.

Status unknown Last updated 27 October 2022

What this trial tests

trial in Prostate Cancer in 15 participants. Status unknown.

Timeline

21 March 2022

Primary endpoint
1 September 2023

1 December 2023

Quick facts

Lead sponsor	European Institute of Oncology
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	15
Start date	21 March 2022
Primary completion	1 September 2023
Estimated completion	1 December 2023
Sites	1 location across Italy

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →
Positron Emission Tomography — all drugs for Positron Emission Tomography →
PSMA — all drugs for PSMA →

Sponsor

European Institute of Oncology

Who can join

18 and older, male only, with Prostate Cancer or Positron Emission Tomography. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to evaluate the diagnostic efficacy and the safety of the combined approach with β-probe and 68Ga-PSMA-11 PET/CT in the correct identification of lymph node metastases, in high-risk prostate cancer patients undergoing radical prostatectomy and pelvic lymph node dissection.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

First Live-Experience Session with PET/CT Specimen Imager: A Pilot Analysis in Prostate Cancer and Neuroendocrine Tumor.
Muraglia L, Mattana F, Travaini LL, Musi G, et al · · 2023 · cited 10× · PMID 36831181 · DOI 10.3390/biomedicines11020645
Surgical radioguidance with beta-emitting radionuclides; challenges and possibilities: A position paper by the EANM.
Fragoso Costa P, Shi K, Holm S, Vidal-Sicart S, et al · · 2024 · cited 9× · PMID 38189911 · DOI 10.1007/s00259-023-06560-2
First-in-human validation of a DROP-IN β-probe for robotic radioguided surgery: defining optimal signal-to-background discrimination algorithm.
Collamati F, Morganti S, van Oosterom MN, Campana L, et al · · 2024 · cited 8× · PMID 38376805 · DOI 10.1007/s00259-024-06653-6
Oligometastatic Prostate Cancer-The Middle Child Syndrome.
Lim EJ, Su M, Saiduzzaman BM, Tay KJ, et al · · 2023 · cited 2× · PMID 38068251 · DOI 10.3390/jcm12237198
Analysis of Clinical Trials and Review of Recent Advances in Therapy Decisions for Locally Advanced Prostate Cancer.
Williams NR. · · 2023 · cited 1× · PMID 37373928 · DOI 10.3390/jpm13060938
First Live-Experience Session with PET/CT Specimen Imager. A pilot analysis in Prostate Cancer and Neuroendocrine Tumor
Muraglia L, Mattana F, Travaini LL, Musi G, et al · · 2023 · DOI 10.20944/preprints202212.0444.v2

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other European Institute of Oncology trials

Trials by the same sponsor.

NCT07374809 — IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER · NA · not yet recruiting
NCT07429851 — CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07508319 — Role of the Immune System in Preventing Laryngeal Cancer · recruiting
NCT07180693 — Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors: · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05596851 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by European Institute of Oncology
Last refreshed: 27 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05596851.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing